ReviewNuclear medicine and molecular imaging2025
The Role of Artificial Intelligence in Advancing Theranostics Dosimetry for Cancer Therapy: a Review.
Review in Nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Dosimetry inJournal of clinical medicine · 2026Review
- Precision theranostics in oncology: integrating antibody-drug conjugates, radioimmunotherapy, and immuno‑PET for adaptive cancer care.Discover oncology · 2026Review
- Recent advances and current landscape of software tools for image analysis and dosimetry in nuclear medicine.EJNMMI physics · 2026Review
- Future of radiotheranostics.BMJ oncology · 2026Review
- The evolution of surrogate microspheres in transarterial radioembolization: from SPECT prediction to multimodal AI-guided precision dosimetry.Theranostics · 2026Review
- Bridging the Gap in Theranostics: Where Do We Stand?Nuclear medicine and molecular imaging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer treatment has greatly benefited from advancements in radiopharmaceutical therapy, which requires precise dosimetry to enhance therapeutic efficacy and minimize risks to healthy tissues. This review investigated the role of artificial intelligence (AI) in theranostic radiopharmaceutical dosimetry, focusing on image quality enhancement, dose estimation, and organ segmentation. An in-depth review of the literature was conducted using targeted keywords searches in Google Scholar, PubMed, and Scopus. Selected studies were evaluated for their methodologies and outcomes. Traditional dosimetry techniques such as organ-level and voxel-based methods are discussed. Deep learning (DL) models based on U-Net, generative adversarial networks, and hybrid transformer networks for image synthesis and generation, image quality improvement, organ segmentation, and radiation dose estimation are reviewed and discussed. While DL shows great potential for enhancing dosimetry accuracy and efficiency, challenges such as the need for accurate dose estimation from theranostic pairs, lack of imaging data, and modeling of radionuclide decay chains must be addressed using DL models. In addition, the optimization and standardization of DL and AI models is crucial for ensuring clinical reliability and should be given high priority to support their effective integration into clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.